BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2010;17:2486-2493. [PMID: 20339946 DOI: 10.1245/s10434-010-1040-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Ainiwaer J, Zhang L, Niyazi M, Awut E, Zheng S, Sheyhidin I, Dai J, Teekaraman Y. Alpha Protein Kinase 2 Promotes Esophageal Cancer via Integrin Alpha 11. BioMed Research International 2022;2022:1-11. [DOI: 10.1155/2022/7676582] [Reference Citation Analysis]
2 Li N, Chen J, Liu Q, Qu H, Yang X, Gao P, Wang Y, Gao H, Wang H, Zhao Z. Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma. PeerJ 2021;9:e11901. [PMID: 34458019 DOI: 10.7717/peerj.11901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ponte LGS, Pavan ICB, Mancini MCS, da Silva LGS, Morelli AP, Severino MB, Bezerra RMN, Simabuco FM. The Hallmarks of Flavonoids in Cancer. Molecules 2021;26:2029. [PMID: 33918290 DOI: 10.3390/molecules26072029] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
4 Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther 2020;5:229. [PMID: 33028804 DOI: 10.1038/s41392-020-00323-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 76] [Article Influence: 5.5] [Reference Citation Analysis]
5 Zhu DS, Dong JY, Xu YY, Zhang XT, Fu SB, Liu W. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling. Med Sci Monit 2020;26:e927106. [PMID: 32804918 DOI: 10.12659/MSM.927106] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Wang X, Cheng G, Zhang T, Deng L, Xu K, Xu X, Wang W, Zhou Z, Feng Q, Chen D, Bi N, Wang L. CHST15 promotes the proliferation of TE‑1 cells via multiple pathways in esophageal cancer. Oncol Rep 2020;43:75-86. [PMID: 31746400 DOI: 10.3892/or.2019.7395] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Javadinia SA, Shahidsales S, Fanipakdel A, Mostafapour A, Joudi-Mashhad M, Ferns GA, Avan A. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy. Curr Pharm Des 2018;24:4646-51. [PMID: 30636576 DOI: 10.2174/1381612825666190110143258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
8 Shi N, Yu H, Chen T. Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway. Onco Targets Ther 2019;12:7637-47. [PMID: 31571914 DOI: 10.2147/OTT.S205457] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
9 Wu K, Hu Y, Yan K, Qi Y, Zhang C, Zhu D, Liu D, Zhao S. microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer. J Cell Physiol 2020;235:1247-58. [PMID: 31267531 DOI: 10.1002/jcp.29040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
10 Xu S, Hui L, Yang N, Wang Y, Zhao N, Jiang XJ. Upregulation of microRNA‑194‑5p inhibits hypopharyngeal carcinoma cell proliferation, migration and invasion by targeting SMURF1 via the mTOR signaling pathway. Int J Oncol 2019;54:1245-55. [PMID: 30720112 DOI: 10.3892/ijo.2019.4711] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA, Alharbi SA, Sethi G, Kumar AP, Kunnumakkara AB. NGAL is Downregulated in Oral Squamous Cell Carcinoma and Leads to Increased Survival, Proliferation, Migration and Chemoresistance. Cancers (Basel) 2018;10:E228. [PMID: 29996471 DOI: 10.3390/cancers10070228] [Cited by in Crossref: 35] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
12 Liu T, Yang K, Yu J, Cao Y, Ren J, Hao J, Pan B, Ma S, Yang L, Cai Y, Wang M, Zhang Y. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma. J Mol Med 2018;96:807-17. [DOI: 10.1007/s00109-018-1663-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Mei LL, Qiu YT, Zhang B, Shi ZZ. MicroRNAs in esophageal squamous cell carcinoma: Potential biomarkers and therapeutic targets. Cancer Biomark. 2017;19:1-9. [PMID: 28269750 DOI: 10.3233/cbm-160240] [Cited by in Crossref: 40] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
14 Li SH, Lu HI, Chang AY, Huang WT, Lin WC, Lee CC, Tien WY, Lan YC, Tsai HT, Chen CH. Angiotensin II type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation. Oncotarget 2016;7:67150-65. [PMID: 27564102 DOI: 10.18632/oncotarget.11567] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
15 Chea C, Miyauchi M, Inubushi T, Febriyanti Ayuningtyas N, Subarnbhesaj A, Nguyen PT, Shrestha M, Haing S, Ohta K, Takata T. Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma. PLoS One 2018;13:e0191683. [PMID: 29381751 DOI: 10.1371/journal.pone.0191683] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
16 Wang C, Wang J, Chen Z, Gao Y, He J. Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chin J Cancer. 2017;36:65. [PMID: 28818096 DOI: 10.1186/s40880-017-0232-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
17 Li SH, Chien CY, Huang WT, Luo SD, Su YY, Tien WY, Lan YC, Chen CH. Prognostic significance and function of mammalian target of rapamycin in tongue squamous cell carcinoma. Sci Rep 2017;7:8178. [PMID: 28811537 DOI: 10.1038/s41598-017-08345-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
18 Liang Y, Chen X, Liang Z. MicroRNA-320 regulates autophagy in retinoblastoma by targeting hypoxia inducible factor-1α. Exp Ther Med 2017;14:2367-72. [PMID: 28962169 DOI: 10.3892/etm.2017.4779] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
19 Jiang Q, Chen J, Zhang B, Niu J, He Y. Prognostic Significance of Periostin and Mammalian Target of Rapamycin (mTOR) in Locally Advanced Esophageal Squamous Cell Carcinoma. Med Sci Monit 2017;23:3200-8. [PMID: 28665915 DOI: 10.12659/msm.904992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
20 Li S, Wang Z, Huang J, Cheng S, Du H, Che G, Peng Y. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis. BMC Cancer 2016;16:877. [PMID: 27835987 DOI: 10.1186/s12885-016-2940-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
21 Chiappini PBO, de Medeiros IUD, Lima LGC, Fregnani JH, Nonogaki S, da Costa WL Jr, Coimbra FJF, Silva MJBE, de Mello CAL, Pinto CAL, Begnami MD. Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas. Arch Med Sci 2017;13:1262-8. [PMID: 29181056 DOI: 10.5114/aoms.2016.60394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
22 Qu Y, Zhao R, Wang H, Chang K, Yang X, Zhou X, Dai B, Zhu Y, Shi G, Zhang H, Ye D. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. Sci Rep 2016;6:23594. [PMID: 27026382 DOI: 10.1038/srep23594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
23 Honjo H, Kaira K, Miyazaki T, Yokobori T, Kanai Y, Nagamori S, Oyama T, Asao T, Kuwano H. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. J Surg Oncol. 2016;113:381-389. [PMID: 26936531 DOI: 10.1002/jso.24160] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
24 Hisamatsu T, Mabuchi S, Sasano T, Kuroda H, Takahashi R, Matsumoto Y, Kawano M, Kozasa K, Takahashi K, Sawada K, Matsuo K, Tamada Y, Morii E, Kitadai Y, Kimura T. The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer. Clin Exp Metastasis 2015;32:789-98. [PMID: 26443563 DOI: 10.1007/s10585-015-9751-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Lu J, Pan Y, Xia X, Gu Y, Lei Y. Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma. Biomed Res Int 2015;2015:417210. [PMID: 26357655 DOI: 10.1155/2015/417210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
26 Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. Head Neck 2016;38 Suppl 1:E844-52. [PMID: 25917382 DOI: 10.1002/hed.24111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
27 Tasioudi KE, Sakellariou S, Levidou G, Theodorou D, Michalopoulos NV, Patsouris E, Korkolopoulou P, Saetta AA. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. APMIS. 2015;123:639-647. [PMID: 25912437 DOI: 10.1111/apm.12398] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
28 Naruse T, Yanamoto S, Yamada S, Rokutanda S, Kawakita A, Kawasaki G, Umeda M. Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma. Pathol Oncol Res 2015;21:765-73. [DOI: 10.1007/s12253-014-9888-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
29 Li SH, Chen CH, Lu HI, Huang WT, Tien WY, Lan YC, Lee CC, Chen YH, Huang HY, Chang AY, Lin WC. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Surgery 2015;157:570-80. [PMID: 25726316 DOI: 10.1016/j.surg.2014.10.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
30 Zhang D, Xiang J, Gu Y, Xu W, Xu H, Zu M, Pei D, Zheng J. Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells. Oncol Lett 2014;8:575-81. [PMID: 25009644 DOI: 10.3892/ol.2014.2186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
31 Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Anticancer Drugs 2013;24:889-98. [PMID: 23838676 DOI: 10.1097/CAD.0b013e328363c64e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
32 Mohamed A, El-Rayes B, Khuri FR, Saba NF. Targeted therapies in metastatic esophageal cancer: advances over the past decade. Crit Rev Oncol Hematol. 2014;91:186-196. [PMID: 24582516 DOI: 10.1016/j.critrevonc.2014.01.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
33 Wang Q, Luo C, Wu X, Du H, Song X, Fan Y. hepaCAM and p-mTOR Closely Correlate in Bladder Transitional Cell Carcinoma and hepaCAM Expression Inhibits Proliferation via an AMPK/mTOR Dependent Pathway in Human Bladder Cancer Cells. Journal of Urology 2013;190:1912-8. [DOI: 10.1016/j.juro.2013.05.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
34 Fountzilas E, Kotoula V, Angouridakis N, Karasmanis I, Wirtz RM, Eleftheraki AG, Veltrup E, Markou K, Nikolaou A, Pectasides D, Fountzilas G. Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer. PLoS One 2013;8:e70429. [PMID: 23950933 DOI: 10.1371/journal.pone.0070429] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
35 Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, Capitani S. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 2014;28:739-48. [PMID: 23892718 DOI: 10.1038/leu.2013.226] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 7.8] [Reference Citation Analysis]
36 Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013;52:1002-9. [PMID: 22950385 DOI: 10.3109/0284186X.2012.718096] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
37 Digklia A, Voutsadakis IA. Targeted treatments for metastatic esophageal squamous cell cancer. World J Gastrointest Oncol 2013; 5(5): 88-96 [PMID: 23799158 DOI: 10.4251/wjgo.v5.i5.88] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
38 Monteiro LS, Delgado ML, Ricardo S, Garcez F, Amaral BD, Warnakulasuriya S, Lopes C. Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2013;115:638-45. [DOI: 10.1016/j.oooo.2013.01.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
39 Clauditz TS, Gontarewicz A, Bokemeyer C, Sauter G, Knecht R, Münscher A, Wilczak W. Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? J Oral Pathol Med 2013;42:769-73. [PMID: 23521157 DOI: 10.1111/jop.12064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
40 Hu J, Xiao L, Li Z, Wang Q, Chang Y, Jin Y. Upregulation of HO-1 is accompanied by activation of p38MAPK and mTOR in human oesophageal squamous carcinoma cells: Alcohol, HO-1, p38MAPK and mTOR in ESCC. Cell Biol Int 2013;37:584-92. [DOI: 10.1002/cbin.10075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Alvarenga AW, Coutinho-Camillo CM, Rodrigues BR, Rocha RM, Torres LF, Martins VR, da Cunha IW, Hajj GN. A comparison between manual and automated evaluations of tissue microarray patterns of protein expression. J Histochem Cytochem 2013;61:272-82. [PMID: 23340270 DOI: 10.1369/0022155413477661] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
42 Kim SH, Jang YH, Chau GC, Pyo S, Um SH. Prognostic significance and function of phosphorylated ribosomal protein S6 in esophageal squamous cell carcinoma. Mod Pathol 2013;26:327-35. [PMID: 22996377 DOI: 10.1038/modpathol.2012.161] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
43 Li M, Sun H, Song L, Gao X, Chang W, Qin X. Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett. 2012;4:1213-1218. [PMID: 23205120 DOI: 10.3892/ol.2012.930] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
44 Kim SH, Chau GC, Jang YH, Lee SI, Pyo S, Um SH. Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma. Hum Pathol 2013;44:226-36. [PMID: 22944293 DOI: 10.1016/j.humpath.2012.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
45 Li SH, Huang EY, Lu HI, Huang WT, Yen CC, Huang WC, Chen CH. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2012;144:1352-9, 1359.e1. [PMID: 22841170 DOI: 10.1016/j.jtcvs.2012.06.049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
46 Khattak MA, Martin HL, Karapetis CS. Targeted therapy for esophagogastric cancers: a review. Onco Targets Ther 2012;5:91-102. [PMID: 22719211 DOI: 10.2147/OTT.S25117] [Reference Citation Analysis]
47 Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer. 2012;106:876-882. [PMID: 22333597 DOI: 10.1038/bjc.2012.36] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
48 Marioni G, Staffieri A, Lora L, Fermo S, Giacomelli L, La Torre FB, Favaretto N, Valentini E, Manzato E, Blandamura S. mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multivariate analyses. Oral Oncol 2012;48:530-4. [PMID: 22285859 DOI: 10.1016/j.oraloncology.2012.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
49 Yeh C, Chuang W, Chao Y, Liu Y, Chang Y, Kuo S, Tseng C, Chang H, Hsueh C. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 2011;458:171-8. [DOI: 10.1007/s00428-010-0994-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]